Oxford Biomedica Solutions
Kevin Luongo has a strong background in quality control, with over 20 years of experience. Kevin is currently the Director of Quality Control at Oxford Biomedica Solutions, a position they have held since 2022. Prior to this, they worked at Homology Medicines, Inc. as the Director of Quality Control from 2018 to 2022, and as the Associate Director of QC Microbiology from 2018 to 2021. Kevin also worked at Takeda Pharmaceuticals as a QC Sr. Scientist in the Vaccine Business Unit from 2016 to 2018, and at Pfizer as the Microbial Control Team Manager from 2015 to 2016. Other roles include working at Shire Pharmaceuticals as a QC Sr. Scientist in Microbiology from 2011 to 2015, and at Pfizer (Formerly Wyeth Biotech) as a QC Scientist II from 2002 to 2011.
Kevin Luongo attended the University of New Hampshire from 1998 to 2002, where they obtained a Bachelor of Science degree in Microbiology.
Oxford Biomedica Solutions
Oxford Biomedica Solutions, LLC is the high-performing, full scope Adeno-Associated Virus (AAV) vector Manufacturing and Innovation joint venture of Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Group”), and Homology Medicines, Inc. (Nasdaq: FIXX) (“Homology”). We offer global pharmaceutical and biotechnology clients innovative manufacturing expertise in AAV and lentiviral-based cell and gene therapies. Oxford Biomedica Solutions LLC provides access to Homology’s innovative and proven end-to-end AAV manufacturing capabilities, and customers also benefit from technical synergies brought in by the Group’s know-how in lentiviral vector manufacturing. This collaborative and complementary vector-based approach has the potential to accelerate our collective mission to improve patients’ lives worldwide.